Skip to main content

Portfolio of Studies

  • Flash study – Commercial Participant Identification Centre (PIC) study investigating the efficacy and safety of a new investigational medication in adults with moderate to severe uncontrolled Asthma.
  • INDIGO (F-Hoffman-La Roche Ltd) – Commercial Phase 3 randomised, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of once-weekly drug administered to participants with obesity or overweight and type 2 diabetes.
  • IPAP – UTI Study – Non-commercial, recruiting study exploring and intervention to reduce local trimethoprim resistance in urinary tract infections.
  • Digital Scribe (EDGE) Study – An evaluation on the impact of digital scribe technology on General Practitioner time use.
  • Genes & Health – Recruiting, non-commercial population-based DNA sequencing, medical records, and recall Bioresource study of British Bangladeshi and British Pakistani communities.
  • Cyted-Health sponge capsule – Recruiting study investigating alternatives to endoscopic diagnostics for Barrett’s oesophagus.
  • MHRA & Genomics England – Yellow Card recruiting study. Pharmacogenomic research in drug safety of GLP-1 receptor agonists.
  • DaRe2Think trial – Pragmatic data-enabled randomized trial investigating if early use of direct oral anticoagulants (DOACS) can prevent strokes, cognitive decline or blood clots.

Page published: 9 April 2026
Last updated: 9 April 2026